Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

被引：14
|
作者：
Gupta, Vikas [1 ]
Harrison, Claire N. [2 ]
Hasselbalch, Hans [3 ]
Pieri, Lisa [4 ]
Koschmieder, Steffen [5 ]
Cervantes, Francisco [6 ]
Bao, Weichao [7 ]
Kalambakas, Stacey [7 ]
Atienza, Edric [7 ]
Gopalakrishna, Prashanth [8 ]
Heidel, Florian H. [9 ]
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
[3] Roskilde Univ Hosp, Dept Hematol, Roskilde, Denmark
[4] Univ Florence, Azienda Osped Univ Careggi, Florence, Italy
[5] RWTH Aachen Univ Hosp, Aachen, Germany
[6] Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Spain
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] Novartis Pharma AG, Basel, Switzerland
[9] Univ Magdeburg, D-39106 Magdeburg, Germany
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.825.825
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
    Gupta, Vikas
    Koschmieder, Steffen
    Harrison, Claire N.
    Cervantes, Francisco
    Heidel, Florian H.
    Drummond, Mark
    Rey, Jerome
    Hurh, Eunju
    Bao, Weichao
    Rampersad, Anita
    Kalambakas, Stacey
    Vannucchi, Alessandro Maria
    BLOOD, 2014, 124 (21)
  • [2] Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study
    Gupta, Vikas
    Wolleschak, Denise
    Hasselbalch, Hans
    Vannucchi, Alessandro Maria
    Koschmieder, Steffen
    Cervantes, Francisco
    Li, Yang
    Dong, Tuochuan
    Wroclawska, Monika
    Bharathy, Savita
    Harrison, Claire
    BLOOD ADVANCES, 2020, 4 (13) : 3063 - 3071
  • [3] A PHASE 1/2 SAFETY AND PRELIMINARY EFFICACY STUDY OF SONIDEGIB (LDE225), A HEDGEHOG PATHWAY INHIBITOR, IN PEDIATRIC AND ADULT PATIENTS WITH RELAPSED OR REFRACTORY MEDULLOBLASTOMA AND OTHER SOLID TUMORS
    Kieran, Mark
    Geoerger, Birgit
    Casanova, Michela
    Chisholm, Julia
    Aerts, Isabelle
    Bouffet, Eric
    Brandes, Alba A.
    Leary, Sarah E. S.
    Sullivan, Michael
    Bailey, Simon
    Cohen, Kenneth
    Mason, Warren
    Kalambakas, Stacey
    Deshpande, Priya
    Tai, Feng
    Hurh, Eunju
    McDonald, Tobey J.
    NEURO-ONCOLOGY, 2013, 15 : 115 - 115
  • [4] Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis
    Couban, Stephen
    Benevolo, Giulia
    Donnellan, William
    Cultrera, Jennifer
    Koschmieder, Steffen
    Verstovsek, Srdan
    Hooper, Gregory
    Hertig, Christian
    Tandon, Maneesh
    Dimier, Natalie
    Templeton, Ian
    Passamonti, Francesco
    BLOOD, 2017, 130
  • [5] A Phase 2 Study of the Safety and Efficacy of INCB050465 in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
    Daver, Naval
    Dao, Kim-Hien
    Assad, Albert
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S351 - S351
  • [6] A phase I study of the smoothened (SMO) antagonist LDE225 in combination with paclitaxel in patients with advanced solid tumors
    Stathis, A.
    Hess, D.
    Xyrafas, A.
    Enoiu, M.
    Berardi, S.
    Von Moos, R.
    Homicsko, K.
    Griguolo, G.
    Joerger, M.
    Mark, M.
    Ackermann, C.
    Sessa, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S67 - S67
  • [7] A Phase I study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastasized pancreatic cancer
    Lee, K.
    Molenaar, R. J.
    Klaassen, R.
    Bijlsma, M. F.
    Weterman, M. J.
    Richel, D. J.
    Wymenga, M.
    van Laarhoven, H. W. M.
    Wilmink, J. W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis
    Gill, Harinder
    Au, Lester
    Leung, Garret Man Kit
    Tsai, Dorothy
    Yim, Rita
    Chin, Lynn
    Li, Vivian
    Lee, Paul
    Leung, Rock Yuk Yan
    Lee, Elaine
    Rienhoff, Hugh Young, Jr.
    Kwong, Yok Lam
    BLOOD, 2023, 142
  • [9] A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL SONIDEGIB (LDE225) VERSUS TEMOZOLOMIDE IN PATIENTS WITH HEDGEHOG PATHWAY-ACTIVATED RELAPSED MEDULLOBLASTOMA
    Kieran, Mark
    Hargrave, Darren
    Wen, Patrick Y.
    Goldman, Stewart
    Amakye, Dereck
    Patton, Margaret
    Tai, Feng
    Moreno, Lucas
    NEURO-ONCOLOGY, 2013, 15 : 115 - 115
  • [10] Phase 2 randomized, double-blind study of sonidegib (LDE225) in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma
    Migden, M.
    Guminski, A.
    Gutzmer, R.
    Dirix, L.
    Lewis, K.
    Combemale, P.
    Herd, R.
    Gogov, S.
    Yi, T.
    Mone, M.
    Kudchadkar, R.
    Trefzer, U.
    Lear, J.
    Sellami, D.
    Dummer, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (03) : E79 - E79
12345